Prof. S. Shakir Jamil Director General CCRUM, Department of AYUSH New Delhi

1. Role of Unani Medicine as Adjuvant therapy in Chronic & Incurable Diseases Prof. S. Shakir Jamil Director General CCRUM, Department of AYUSH New Delhi 10th Knowledge Millenium Summit-2013 “Curing the Incurables: Sharing of Innovation” 16th January, 2013, Vigyan Bhavan, New Delhi

2. Origin & Caravan • Unani System of Medicine originated from Greece • The philosophical doctrines of the System was laid down by Hippocrates. (460-377 BC) • Arab, Central Asian and European countries contributed to the system. • From Central Asia Unani Medicine traversed to India

3. Present Scenario • Today, India is the world leader in Unani Medicine having largest set up of educational, healthcare and research facilities. • Unani medicine is also recognized, practiced and popular in Pakistan, Bangladesh, Malaysia, Sri Lanka and South Africa. • Also Practiced in Kuwait, Dubai & Saudi Arabia etc.

4. Fundamental concepts • Tabiyat (Medicatrix naturae) • Mizaj (Temperament) • Akhlat (Body Humours) • Usool-e- Ijaj (Principles of treatment) including Ilaj-bit-Tadbir (Regimenal Therapy)

5. Research & Development • CCRUM • Central Council for Research in Unani Medicine (CCRUM) was established by Government of India as apex organization for Research and Development activities in Unani System of Medicine in 1979. • The Council is an autonomous organization under Department of AYUSH, Ministry of Health & Family Welfare, Govt of India.

7. Central Council for Research in Unani Medicine

8. CCRUM - Mandate • Research in Unani Medicine on scientific lines. • To initiate, aid, develop and coordinate scientific research of Unani Medicine. • To finance researches meant for furtherance of objective of the CCRUM. • To exchange information with other institutions. • To prepare and publish literature on Unani medicine. 8

9. Research Programmes Pre-clinical/Safety Studies Clinical Research Fundamental aspects of Unani Medicine Drug Standardization including SOPs for Unani drugs Literature including Medico-historical Research Ethno-botanical Survey, Collection and Cultivation of Unani Medicinal Plants IEC and other Research oriented programmes

10. Pre-Clinical & Clinical Research Pharmacological action/safety evaluation 22 drugs Number of diseases clinically studied 22 Clinical trials completed 13 drugs Number of drugs under trial 30

11. Validation of Pharmacopoeal drugs Validation of safety & efficacy of Unani pharmacopoeial Drugs. Number of formulations 25 Number of diseases under study 10

12. Leads in Clinical Research • Bars (Vitiligo) • Naar-e- Farsi (Eczema) • Taqashshur-e-Jild (Psoriasis ) • Zeequn-Nafas (Bronchial asthma ) • Zaght-ud- Dam Qawi (Hypertension) • Daa-ul-Feel (Filariasis) • Iltehaab-e-Mafasil (Rheumatoid arthritis) • Iltehaab-e-Tajaweef-e-Aanaf (Sinusitis)

13. Validation of Unani Fundamentals • Study on susceptibility of acquiring diseases in relation to • Mizaj (temperament). • Study on molecular interpretation of individual • temperament at CRIUM, Hyderabad • in collaboration • with Center for Cellular and Molecular Biology, CSIR, Hyderabad.

14. Drug Standardization including SOPs for Unani drugs Unani single drugs standardized 298 SOPs developed for compound Unani formulations 100

15. Patents Patents awarded 08 drugs Patents filed 41 drugs

16. Literary Research

17. Collaboration/support with other institutions • All India Institute of Medical Sciences, (AIIMS) New Delhi. • VallabhBhai Patel Chest Institute, University of Delhi, New Delhi. • JamiaHamdard (Hamdard University), New Delhi. • KGMC, Lucknow. • Ibn-e-Sina Academy, Aligarh. • Centre of Liver diseases Deccan Med. College, Hyderabad • Taramani Hospital & Res. Centre, Chennai. • Osmania General Hospital Hyderabad.

18. Contd.. Collaboration/support with other institutions • With the financial support by DST for creating research infra-structure two facilities were created: • Clinical Research facilitiy at CRI, Hyderabad. • Pre-clinical research facilitiy at RRI, Srinagar.

19. Collaboration with Foreign Institutions Centre for Research in Indian Systems of Medicine (CRISM) in University of Mississippi, USA UNANI CHAIR at University of Western Cape, South Africa UNANI CHAIR at Sri Lanka is in process

20. Unani Medicine as Adjuvant therapy Thrust areas: • Immuno-modulation • To prevent drug toxicity • To improve Quality of Life

21. Contd.. Unani Medicine as Adjuvant therapy Areas • Cognitive impairment • Tuberculosis (especially MDR TB) • Cancer • HIV / AIDS

22. Unani Medicine as Adjuvant therapy Contd.. Study 1 Cognitive impairment Title: Evaluation of a Unani Formulation for Improving Cognitive Impairment in Children with Cerebral Palsy and Mental Retardation • The study was conducted at Majeedia Hospital, Jamia Hamdard in collaboration with UDAAN an NGO working for disabled children. • This was a controlled study in which both groups were given physiotherapy and special education but one group was given Unani formulation and other group HBOT. • The study was conducted on current clinical parameters following the GCP. Objective: To prove efficacy of Unani formulation in the treatment of Neurodevelopmental disabilities with special emphases on cognitive improvement in Cerebral Palsy (C.P.) and/or Mental Retardation (M.R.). Outcome: • Long term amelioration of associated behavioural and neurological problems • Improvement in memory and cognitive functions • Improvement in musculo-skeletal deformities

23. Unani Medicine as Adjuvant therapy Contd… Study 2 Title: Study on management of Pulmonary Tuberculosis with herbal Unani product (0394) as an adjuvant drug . • The study was sponsored by Panacea Biotech and conducted at Majeedia Hospital, Jamia Hamdard, Hamdard Nagar, New Delhi. • This was a controlled study in which ATT was given to both groups and only one group was given Unani adjuvant formulation along with ATT. • The study was conducted on current clinical parameters following the GCP. Objective: To evaluate the efficacy of Unani formulation in enhancement of resolution rate in Pulmonary Tuberculosis including MDR. Outcome: • Fast resolution of infiltration in chest. • Faster sputum clearance for AFB. • Better response in MDR cases.

24. Contd… Unani Medicine as Adjuvant therapy Study 3 Title: Clinical evaluation of a Unani formulation for prevention ofhepato-nephro toxicity in Pulmonary Tuberculosis. • (The study was conducted at Majeedia Hospital, Jamia Hamdard. • This was a controlled study in which both groups were given ATT and one group was Unani Hepato-protective formulation. • The study was conducted on current clinical parameters following the GCP. Objective: To evaluate efficacy of Unani formulation in the treatment of Pulmonary Tuberculosis with reference to prevention of hepato-nephro toxicity.

25. Contd… Unani Medicine as Adjuvant therapy • Cancer • Objective of the study is to prevent the hepato-nephro toxicity during chemotherapy and to improve the Quality of Life in Cancer patients. • Feasibility study has been completed. Detailed planning and protocol designing at CRIUM, Lucknow is under progress.

26. Contd… Unani Medicine as Adjuvant therapy • HIV / AIDS • Objective of the study is to improve, enhance and potentiate body immunity and to improve the Quality of Life in HIV/AIDS patients. • Feasibility study has been conducted. Detailed planning and protocol designing at RRIUM, Mumbai in collaboration with J.J. Hospital, Mumbai.

27. Thank You